https://www.fresenius.com en-us Mon, 27 May 2024 20:00:00 +0200 Mon, 27 May 2024 20:00:00 +0200 Mon, 27 May 2024 20:00:00 +0200 <![CDATA[Fresenius Announces FDA Acceptance for Review of Denosumab Biosimilar Application]]> Wed, 08 May 2024 13:10:01 +0200 <![CDATA[Fresenius exits its Investment Company Vamed ]]> Wed, 08 May 2024 13:00:00 +0200 <![CDATA[Fresenius raises outlook for fiscal 2024 due to excellent first quarter ]]> website. Following the deconsolidation of Fresenius Medical Care, Group financial figures are presented in accordance with IAS 28 (at equity method) since December 1, 2023. The proportionate share of 32% of Fresenius Medical Care is presented as a separate line in Fresenius Group’s P&L and balance sheet. Dividends received from Fresenius Medical Care will also be reported as a separate line as part of the cash flow statement. Moreover, IAS 28 requires a full purchase price allocation (PPA). The accounting for the PPA is treated as special item. For reasons of simplification and comparability, Fresenius presents net income with and without Fresenius Medical Care`s equity result. Information on the performance indicators are available on our website at https://www.fresenius.com/alternative-performance-measures. Consolidated results for Q1/24 as well as for Q1/24 include special items. These concern: revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, transaction costs for mAbxience and Ivenix, costs in relation to the change of legal form of Fresenius Medical Care, the transformation of Fresenius Vamed, legacy portfolio adjustments, special items at Fresenius Medical Care, and impact of PPA equity method Fresenius Medical Care. The special items shown within the reconciliation tables are reported in the Corporate/Other segment. Growth rates of Fresenius Kabi and Fresenius Helios are adjusted. Adjustsments relate to the divestment of the fertility services group Eugin and the hospital stake in Peru at Fresenius Helios and Helios Spain as well as to hyperinflation in Argentina at Fresenius Kabi. Accordingly, growth rates of the Fresenius Group are also adjusted. Conference call and Audio webcast As part of the publication of the results for Q1/24, a conference call will be held on May 8, 2024 at 1:30 p.m. CET (7:30 a.m. EST). All investors are cordially invited to follow the conference call in a live audio webcast at https://www.fresenius.com/investors. Following the call, a replay will be available on our website.   Michael Sen, CEO of Fresenius: “Fresenius has made an excellent start into the year and our focus on Fresenius Kabi and Fresenius Helios is paying off. We are confident to maintain our growth momentum and raise our outlook for the full year. With the exit from Vamed, our strategic portfolio restructuring is completed as planned. Fresenius is already a simpler, stronger, and more innovative company due to the consistent implementation of #FutureFresenius. We now have even more opportunities to offer world-class therapies and improve people’s health.” #FutureFresenius: Exit from Investment Company Vamed concludes strategic portfolio measures The exit from the Investment Company Vamed completes the strategic portfolio restructuring as part of #FutureFresenius. The exit is carried out in three parts: 1) The already announced sale of 67 % of Vamed’s rehabilitation business to the private equity company PAI. Closing of this transaction is expected in the second half of 2024 2) Vamed’s operations in Austria to be sold to an Austrian consortium of the construction companies Porr and Strabag for a total purchase price of €90 million. 3) The Health Tech Engineering (HTE) segment, which is responsible for the international project business and accounts for around 15% of Vamed's revenue, will gradually be scaled back in an orderly manner. The process should largely be completed by 2026. Until then, the business will be reported as a special item outside Fresenius' core business. Current project contracts will be fulfilled. Vamed’s High-End-Services (HES) which offers services for Fresenius Helios and other hospitals, will be transferred to Fresenius. HES is a stable business with good growth prospects and accounts for around 30% of Vamed's revenues. The profitability of HES is in the mid-single-digit percentage range. The divestments of the rehabilitation business and the operations in Austria lead to non-cash special items of around €0.6 billion. Due to the exit from the project business, a high triple-digit-million euro amount of special items are expected, which are spread over the next few years and mostly cash-effective. As of Q2 2024, Vamed will no longer be a reporting segment of Fresenius. In addition to reducing complexity, this step is expected to improve the Group's profitability by more than 50 basis points. It will also reduce net debt and increase the Group's return on invested capital (ROIC). Last but not least, the transparency and quality of earnings will be significantly enhanced. After exiting from Vamed, Fresenius will consist of the two Operating Companies Fresenius Kabi and Fresenius Helios (each with 100% ownership share) and the Investment Company Fresenius Medical Care (32% ownership share). Cost savings program fully on track The groupwide cost savings program progressed is fully on track. Under the program, Fresenius realized ~€25 million incremental structural cost savings at EBIT level in Q1/24. In the same period, one-time costs of ~€15 million incurred to achieve these savings. Fresenius expects to achieve annual sustainable cost savings of ~€400 million at EBIT level by 2025. So far, Fresenius reached ~€305 million of cumulative structural cost savings. To reach this target, one-time costs between ~€80 and €100 million are anticipated between 2024 and 2025. For 2024, total cost savings of ~€330 to €350 million are expected. This corresponds to incremental cost savings of ~€50 to €70 million in 2024 compared to 2023. The programs continue to target all business segments and the Corporate Center. Key elements include measures to optimize sales and administrative costs, fostering digitalization as well as improve procurement processes.   Group sales and earnings development Group revenue increased by 4% (6% in constant currency) to €5,704 million (Q1/23: €5,546 million). Organic growth was 6%1 driven by an ongoing strong performance of our Operating Companies. Currency translation had a negative effect of 2% on revenue growth. In Q1/24, revenue of the Operating Companies increased by 5% (7% in constant currency) to €5,216 million (Q1/23: €5,039 million). Group EBITDA before special items increased by 13% (13% in constant currency) to €924 million (Q1/232: €828 million). Group EBIT before special items increased by 15% (15% in constant currency) to €633 million (Q1/232: €554 million) mainly driven by the good earnings development at the Operating Companies and the continued progress of the groupwide cost savings program. The EBIT margin before special items was 11.1% (Q1/231: 10.0%). Reported Group EBIT was €559 million (Q1/23: €526 million). The Operating Companies showed an 9% increase of EBIT before special items (9% in constant currency) to €631 million (Q1/232: €581 million) with an EBIT margin of 12.1% (Q1/232: 11.5%). 1 Organic growth rate adjusted for the divestment of the fertility services group Eugin, the hospital stake in Peru, and accounting effects related to Argentina hyperinflation. 2 Before special items 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA    Group net interest before special items increased to -€115 million (Q1/231: -€87 million) mainly due to financing activities in a higher interest rate environment. Group tax rate before special items was 24.5% (Q1/231: 24.4%). Net income1 from deconsolidated Fresenius Medical Care operations before special items increased by 25% (33% in constant currency) to €60 million (Q1/232: €48 million). Group net income2 before special items increased by 10% (11% in constant currency) to €429 million (Q1/232: €389 million). The increase was driven by the operating strength which outpaces higher interest. Group net income1 before special items excluding Medical Care increased by 8% (8% in constant currency) to €369 million (Q1/232: €341 million). Reported Group net income2 decreased to €278 million (Q1/232: €346 million). Negative effects from the Purchase Price Allocation (PPA) and other negative special items at Fresenius Medical Care as well as the Vamed transformation had a negative impact on the Group net income income1. Earnings per share2 before special items increased by 10% (11% in constant currency) to €0.76 (Q1/232: €0.69). Reported earnings per share2 were €0.49 (Q1/23: €0.61). 1 Before special items 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA For a detailed overview of special items please see the reconciliation tables at Financial Results.   Group Cash flow development Group operating cash flow was €2 million (Q1/23: €32 million). The first quarter is usually the softest in the course of the year. In Q1/24 the soft operating cash flow was mainly driven by temporarily higher working capital, in particular due to nursing budget related receivables built ups at Helios Germany. Group operating cash flow margin was 0.0% (Q1/23: 0.6%). Free cash flow before acquisitions, dividends and lease liabilities decreased to -€194 million (Q1/23: -€180 million). Free cash flow after acquisitions, dividends and lease liabilities improved to -€103 million (Q1/23: -€258 million). Fresenius Kabi’s operating cash flow increased to €157 million (Q1/23: €21 million) with a margin of 7.7% (Q1/23: 1.1%) mainly driven by an improved working capital management. Fresenius Helios’ operating cash flow decreased to -€117 million (Q1/23: €108 million) and was impacted by higher working capital in particular driven by temporary nursing budget related receivables built-ups at Helios Germany. The operating cash flow margin was -3.7% (Q1/23: 3.5%). Fresenius Vamed’s operating cash flow improved to -€10 million (Q1/23: -€68 million) with a margin of -1.8% (Q1/23: -11.7%). The cash conversion rate (CCR), which is defined as the ratio of adjusted free cash flow1 to EBIT before special items was 1.0 in Q1/24 (LTM) (Q1/23: 0.9 LTM). This positive development is due to the increased cash flow focus across the Group. 1 Cash flow before acquisitions and dividends; before interest, tax, and special items   Group leverage Group debt decreased by 8% (8% in constant currency) to €14,504 million (Dec. 31, 2023: € 15,830 million) mainly related to the repayment of debt. Group net debt increased by 2% (2% in constant currency) to € 13,485 million (Dec. 31, 2023: € 13,268 million) which is mainly related to the cash flow development at Fresenius Helios, particularly driven by temporary receivables built ups related to the nursing budget at Helios in Germany. As of March 31, 2024, the net debt/EBITDA ratio was 3.75x1,2 (Dec. 31, 2023: 3.76x1,2), a further reduction compared to Q4/23 and mainly driven by the good EBITDA development. Compared to Q1/23 (3.96x1,2) this is a 21 bps reduction. Fresenius expects the net debt/EBITDA3 ratio to be within the self-imposed corridor of 3.0 to 3.5x by the end of 2024. This is expected to be driven by reducing net debt and by the operational performance at the Operating Companies. ROIC increased to 5.5% in Q1/24 (Q1/23: 5.2%) mainly due to the EBIT improvement. The Operating Companies improved ROIC to 5.8% (Q1/23: 5.5%). 1 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend 2 Before special items 3 At expected average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; excluding further potential acquisitions/divestitures; before special items; including lease liabilities, including Fresenius Medical Care dividend For a detailed overview of special items please see the reconciliation tables at Financial Results.   Operating Company Fresenius Kabi Revenue increased by 9% in constant currency (3% reported) to €2,051 million (Q1/23: €1,991 million). The reported revenue growth is mainly driven by negative currency translation effects related to the US dollar and the hyperinflation in Argentina. Organic growth was 9%1. This strong performance was driven in particular by the Biopharma business as well as by Nutrition. Revenue of the Growth Vectors (MedTech, Nutrition and Biopharma) increased by 4% (14% in constant currency) to €1,089 million (Q1/23: €1,051 million). Organic growth was outstanding at 13%. In Nutrition, organic growth of 8% benefited from the good development in the US and was driven by many other international markets. Whereas China continued to be impacted by indirect effects of the government’s countrywide anti-corruption campaign and direct effects of the soft economy. Biopharma showed excellent organic growth of 117% driven by successful product launches in Europe and the US, as well as licensing agreements. MedTech showed organic growth of 1% given the high prior-year level. 1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation. 2 Before special items Growth rates adjusted for Argentina hyperinflation.   Revenue in the Pharma (IV Drugs & Fluids) business increased by 2% (4% in constant currency; organic growth: 5%) and amounted to €962 million (Q1/23: €940 million). The solid organic growth was mainly driven by the positive development across many regions including the US. EBIT1 of Fresenius Kabi increased by 7% (8% in constant currency) to €310 million (Q1/23: €289 million) mainly due to the good revenue development, the EBIT break-even result of the Biopharma business, and ongoing progress of the cost saving initiatives. EBIT margin1 was 15.1% (Q1/23: 14.5%) and thus within the structural EBIT margin band. EBIT1 of the Growth Vectors increased by 29% (constant currency: 17%) to €124 million (Q1/23: €96 million) due to the EBIT break-even result of the Biopharma business and the good revenue development. EBIT1 margin was 11.4% (Q1/23: 9.2%). EBIT1 in the Pharma business increased 4% (constant currency: 6%) to €206 million (Q1/23: €197 million) due to the very well-progressing cost saving initiatives and the good revenue development. EBIT1 margin was 21.4% (Q1/23: 21.0%). 1 Before special items Growth rates adjusted for Argentina hyperinflation. For a detailed overview of special items please see the reconciliation tables at Financial Results.     Operating Company Fresenius Helios Revenue increased by 6% (5% in constant currency) to €3,184 million (Q1/23: €3,066 million). Organic growth was 5%. Revenue of Helios Germany increased by 4% (in constant currency: 4%) to €1,903 million (Q1/23: €1,828 million), mainly driven by solid admissions numbers and favourable price effects. Organic growth was 4%. Revenue of Helios Spain increased by 10% (8% in constant currency) to €1,281 million (Q1/23: €1,170 million) driven by ongoing strong activity levels and positive price effects. Organic growth was 7%1. The clinics in Latin America also showed a good performance. EBIT2 of Fresenius Helios increased by 14% (14% in constant currency) to €353 million (Q1/23: €311 million) with an EBIT margin2 of 11.1% (Q1/23: 10.1%). EBIT of Helios Germany increased by 32% to €205 million (Q1/23: €155 million) with an EBIT margin of 10.8% (Q1/23: 8.5%) in particular driven by the phasing of the Government relief funding for higher energy costs as well as the good revenue development and the progressing cost savings program. 1 Before special items Growth rates adjusted for the divestment of the fertility services group Eugin and the hospital stake in Peru For a detailed overview of special items please see the reconciliation tables at Financial Results.   EBIT1 of Helios Spain decreased by 6% (7% in constant currency) to €149 million (Q1/23: €157 million). EBIT1 was impacted by the phasing due to the calendar variation related to the Easter week and related lower activities and mix effects as well as a high prior-year level. Despite the Easter effect, the EBIT margin1 was 11.6% (Q1/23: 13.4%). As part of the portfolio optimization, the sale of the fertility services group Eugin was completed on January 31, 2024. The divestment of the majority stake in the hospital Clínica Ricardo Palma hospital in Lima, Peru, was completed on April 23, 2024. The sale marks Fresenius’ exit from the Peruvian hospital market.   Fresenius Vamed Further progress was made in Q1/24 with the far-reaching restructuring program to increase Fresenius Vamed’s profitability which was initiated in 2023. Revenue from continued business was €514 million in Q1/24. Organic growth of the continued business increased 1% driven by the positive development of the Services business offsetting the negative effects of the Project business. Total revenue of Fresenius Vamed was €561 million (Q1/23: €583 million) and declined by 4% (-4% in constant currency). EBIT1 was at €2 million in Q1/24 (Q1/231: -€27 million), thus showing a significant year-over-year improvement and making it the third consecutive quarter of positive EBIT. The EBIT margin1 in Q1/24 was 0.4% (Q1/231: -4.6%). The ongoing transformation resulted in negative special items of €47 million in Q1/24 mainly related to cessation of activities, asset re-evaluations and restructuring costs resulting in write-downs and provisions. The negative special items were predominantly booked as non-cash items. 1 Before special items Growth rates adjusted for the divestment of the fertility services group Eugin and the hospital stake in Peru   Group and segment outlook for 20241 Fresenius raises its outlook for FY/24 based on the excellent first quarter and improved prospects for the ramainder of the year. For 2024, Group organic revenue growth2 is now expected to grow between 4% to 7% (previous: 3% to 6%). Group constant currency EBIT3,4 is expected to grow in the rage of 6% to 10% (previous: 4% to 8%). Fresenius Kabi now expects organic revenue growth in a mid-to high-single-digit percentage range in 2024 (previous: mid-single-digit percentage range). The EBIT margin4 is now expected to be in a range of 15% to 16% (previously: around 15%) (structural margin band: 14% to 17%). Fresenius Helios expects organic revenue to grow in a low to mid-single digit percentage range in 2024. The EBIT margin4 is expected to be within the structural margin band of 9% to 11%. The adjustment of the Group outlook also reflects the fact that the forecast is now given without Fresenius Vamed, i.e. exclusively for the Operating Companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed's rehabilitation business, Fresenius has initiated its structured exit from its Investment Company Fresenius Vamed. 1 For the prior-year basis please see table “Basis for Guidance for 2024” 2 2023 base: €20,307 million 3 2023 base: €2,266 million 4 Before special items   Basis for Guidance for 2024      ]]> Fri, 03 May 2024 00:15:00 +0200 <![CDATA[Fresenius divests Vamed’s rehabilitation business]]> Tue, 23 Apr 2024 15:00:00 +0200 <![CDATA[Fresenius successfully completes divestment of hospital stake in Peru]]> Mon, 15 Apr 2024 23:00:00 +0200 <![CDATA[Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.]]> Thu, 04 Apr 2024 20:30:13 +0200 <![CDATA[mAbxience and Teva announce strategic global license agreement for biosimilar oncology treatment]]> Thu, 04 Apr 2024 20:00:00 +0200 <![CDATA[Fresenius Management Board buys own shares]]> Mon, 18 Mar 2024 17:00:00 +0100 <![CDATA[Fresenius Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate]]> Thu, 07 Mar 2024 17:00:00 +0100 <![CDATA[Fresenius Kabi’s biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and subcutaneous tocilizumab biosimilar approved by the FDA ]]> Wed, 28 Feb 2024 21:00:00 +0100 <![CDATA[Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP in the U.S.]]> Wed, 21 Feb 2024 14:00:00 +0100 <![CDATA[Fresenius closes 2023 with a strong fourth quarter and expects accelerated earnings growth in 2024 due to increasing momentum from #FutureFresenius]]> Tue, 20 Feb 2024 17:58:04 +0100 <![CDATA[Fresenius with top result in climate ranking, water ranking improved]]> Mon, 05 Feb 2024 19:00:00 +0100 <![CDATA[mAbxience announces CDMO agreement with Biosidus for the treatment of Fabry disease ]]> Wed, 31 Jan 2024 23:22:00 +0100 <![CDATA[Fresenius successfully completes divestment of fertility services group Eugin]]> Mon, 29 Jan 2024 22:00:00 +0100 <![CDATA[Fresenius Kabi launches generic drug for the treatment of serious fungal infections in the U.S.]]> Fri, 12 Jan 2024 18:00:00 +0100 <![CDATA[Fresenius signs Zero Health Gaps Pledge]]> Wed, 20 Dec 2023 15:00:00 +0100 <![CDATA[mAbxience announces licensing agreement with Intas for Etanercept biosimilar ]]> Fri, 15 Dec 2023 15:36:06 +0100 <![CDATA[Fresenius Helios strengthens operational focus in digitalization]]> Thu, 14 Dec 2023 21:00:00 +0100 <![CDATA[Fresenius Kabi enters into multiyear supply and service agreement for its Ivenix Infusion System]]>